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Abstract
Aims Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are main causes of dyspnoea, and echocardiog-
raphy and spirometry are essential investigations for these diagnoses. Our aim was to determine the prevalence of HF and
COPD in a general population, also how the diseases may be identified, and to what extent their clinical characteristics differ.
Methods and results In the seventh survey of Tromsø study (2015–16), subjects aged 40 years or more were examined with
echocardiography, spirometry, lung sound recordings, questionnaires, including the modified Medical Research Council
(mMRC) questionnaire on dyspnoea, and N‐terminal pro‐brain natriuretic peptide analysis. A diagnosis of HF (HF with reduced
ejection fraction, HF with mid‐range ejection fraction, or HF with preserved ejection fraction) or COPD was established accord-
ing to current guidelines. Predictors of HF and COPD were evaluated by logistic regression and receiver operating characteristic
curve analysis. A total of 7110 participants could be evaluated for COPD, 1624 for HF, and 1538 for both diseases.
Age‐standardized prevalence of HF was 6.8% for women and 6.1% for men; the respective figures for COPD were 5.2% and
5.1%. Among the 1538 evaluated for both diseases, 139 subjects fulfilled the HF criteria, but only 17.1% reported to have
the disease. Of those fulfilling the COPD criteria, 31.6% reported to have the disease. Shortness of breath at exertion was a
frequent finding in HF; 59% of those with mMRC ≥2 had HF, while such shortness of breath was found in 24% among those
with COPD. Reporting mMRC ≥2 had an odds ratio for HF of 19.5 (95% confidence interval 11.3–33.7), whereas the odds ratio
for COPD was 6.3 (95% confidence interval 3.5–11.6). Current smoking was the strongest predictor of COPD but did not predict
HF. Basal inspiratory crackles were significant predictors of HF in multivariable analysis. Among the subtypes of HF, an age
<70 years was most frequently found in HF with reduced ejection fraction, in 51.7%. Clinical scores based on the predictive
value in multivariable analysis of history, symptoms, and signs predicted HF and COPD with areas under the curve of 0.833
and 0.829, respectively.
Conclusions Study participants with HF and COPD were in most cases not aware of their condition. In general practice, when
an elderly patient present with shortness of breath, both diseases should be considered. Previous cardiovascular disease
points at HF, while a history of smoking points at COPD. The threshold should be low for ordering echocardiography or spirom-
etry for verifying the suspected cause of dyspnoea.
Keywords Epidemiology; Heart failure; Chronic obstructive pulmonary disease; Spirometry; Echocardiography; Symptoms; Identifi-
cation; Biomarkers
Received: 12 June 2020; Revised: 29 July 2020; Accepted: 15 September 2020
*Correspondence to: Henrik Schirmer, Department of Cardiology, Akershus University Hospital, 1478 Nordbyhagen, Norway. Tel: +47 99264338.
Email: henrik.schirmer@medisin.uio.no
ORIG INAL RESEARCH ART ICLE
© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any me-
dium, provided the original work is properly cited and is not used for commercial purposes.
ESC HEART FAILURE
ESC Heart Failure 2020; 7: 4139–4150
Published online 7 October 2020 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.13035
Introduction
Heart failure (HF) and chronic obstructive pulmonary disease
(COPD) are two of the most common chronic diseases and
are leading causes of morbidity and mortality worldwide with
high social and economic negative impact. Exacerbations of
HF and COPD are major causes of admittance to emergency
departments.1,2 HF and COPD are not curable diseases, but
early diagnosis can lead to preventive measures, including
smoking cessation,3 that can prolong life and reduce the
number of acute exacerbations.2,4
Heart failure and COPD might be underdiagnosed at an
early stage partly due to unspecific early symptoms.5 A
cardinal symptom for HF, exertional dyspnoea,6 is also
shared by COPD, and also, cough may be present in both
diseases.7 HF and COPD may overlap and increasingly by
age.8,9
Clinicians take chest signs like crackles and wheezes into
account when HF or COPD is suspected, but the sensitivity
and specificity of these findings are regarded to be low.6,10
This study is based on the seventh survey of the Tromsø
study where recording of lung sounds was included among
the clinical investigations.11
The aim of this study was to determine how abnormal lung
sounds and respiratory symptoms, shortness of breath in par-
ticular, may predict HF and COPD, as identified by current
guidelines and to what extent the occurrence of these dis-
eases overlap in a general population.
Methods
Study population
The Tromsø study was established in 1974 with the main
aim of understanding the role of modifiable cardiovascular
disease risk factors. Seven waves of the study have been
carried out with the last health survey performed in
2015–16. Main features of the methodology and study
design have been described previously.12 In this
cross‐sectional study, our sample consists of randomly
selected participants attending the second visit of the sev-
enth survey of the Tromsø study (Tromsø 7), between
May 2015 and October 2016. All Tromsø residents 40 years
or older (n = 32 591) received a postal invitation to partic-
ipate in the first visit of Tromsø 7. A random sample was
selected for the second visit including 20% of those aged
40–59 years and 60% of those aged 60–84 years, and,
among these, those who attended the first visit were
invited. In addition, individuals who had participated in
echocardiography in previous surveys of the study were in-
vited to obtain repeated measurements.
Data collection
The following information on participant’s diseases and risk
factors was retrieved from self‐administered questionnaires
at the first visit: myocardial infarctions, angina, atrial fibrilla-
tion, arterial hypertension, diabetes, COPD, and asthma.
Smoking was categorized as never smoked, previous, and cur-
rent smokers, and the participants answered the question
‘Do you cough about daily for some periods of the year?’.
At the second visit, before spirometry, the participants
answered modified Medical Research Council (mMRC) ques-
tionnaire on dyspnoea.13 Dyspnoea was further characterized
using the question: ‘How is your breathing today
compared to normal?’. Serum levels of N‐terminal pro‐brain
natriuretic peptide (NT‐proBNP) and C‐reactive protein were
measured with reagents from Roche Diagnostics, Norway.
The age‐related reference values of NT‐proBNP (97.5 percen-
tile in a healthy population) were provided by Roche Diagnos-
tics (Appendix A).
Echocardiographic assessment was performed by an expe-
rienced echo technician using a GE Vivid E9 scanner (GE
Medical, Horten, Norway). Echopac version 113 (GE Medical)
was used for offline image reading performed by M. S.
Ultrasound examination was performed according to
guidelines14 in the left lateral decubitus position. Left ventric-
ular myocardial mass index was estimated by normalizing left
ventricular mass and to height raised to allometric power of
2.7.
Echo markers of diastolic dysfunction in individuals with
normal left ventricular ejection fraction (LVEF) were as fol-
lows: average E/e′ >14; septal e′ velocity <7 cm/s or lateral
e′ velocity <10 cm/s; tricuspid regurgitation velocity
>2.8 m/s; and left atrial volume index >34 mL/m2.
Spirometry was performed using SensorMedics Vmax
20c Encore (VIASYS Healthcare Respiratory Technologies,
Yorba Linda, CA, USA). Calibration was performed daily. We
followed the standards of the American Thoracic
Society/European Respiratory Society.15 Tests with forced ex-
piratory volume in 1 s (FEV1) <0.3 L and with expiration last-
ing less than 3 s were regarded invalid. Post‐bronchodilator
measurements were not carried out. We used the Global
Lung Function Initiative (GLI 2012) as a reference with the
fifth percentile among healthy never smokers as lower limit
of normal (LLN).16 We registered arterial oxygen saturation
(Sp02) with a pulse oximeter Onyx II model 9550 (Nonin Med-
ical, Inc., Plymouth, MN, USA) after resting 15 min. The
highest value after three measurements was registered.
Medication for asthma and COPD should be taken as usual.
Lung sounds were recorded at six locations of the chest,
15 s at each site, with a Sennheiser microphone inserted in
the tube of a Littmann Classic II stethoscope. Presence of
wheezes and crackles (also called rales or crepitations) during
inspiration and expiration was determined by clinicians inde-
pendently classifying the recordings blinded for other
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information; details on recording sites and classification of
the sounds have recently been published.11 Basal inspiratory
crackles heard bilaterally were a category used in the
analysis.17
Definition of heart failure and chronic obstructive
pulmonary disease
Heart failure was defined according to the latest European
Society of Cardiology (ESC) guidelines2 into three types: heart
failure with reduced ejection fraction (HFrEF) characterized
by LVEF <40% and presence of dyspnoea (mMRC ≥1); heart
failure with mid‐range ejection fraction (HFmrEF) with LVEF
40–49%, dyspnoea, serum NT‐proBNP >125 pg/mL, and any
of the following: structural heart disease/diastolic dysfunc-
tion; and heart failure with preserved ejection fraction
(HFpEF) with LVEF ≥50%, dyspnoea, serum NT‐proBNP
>125 pg/mL, and any of the following: structural heart
disease/diastolic dysfunction.
Structural heart disease included left ventricular hypertro-
phy and/or left atrial enlargement. Diastolic dysfunction was
defined by joint European Society of Cardiovascular Imaging
and American Society of Echocardiography guidelines.18
A diagnosis of COPD was established when FEV1/forced
ventilator capacity (FVC) was lower than normal (LLN, the
5% percentile in a healthy non‐smoking population), and
the participants had answered yes to the question ‘Do you
get short of breath when hurrying on a level surface or walk-
ing up a slight hill?’ (mMRC = 1 or higher) or to the question
‘Do you cough about daily for some periods of the year?’.19
Sensitivity analysis
Evaluation of predictors of HF and COPD was mainly per-
formed in subjects classified for both diagnoses. In addition,
we evaluated HF predictors in all subjects that could be clas-
sified according to the HF criteria and likewise COPD predic-
tors in all subjects that could be classified according to
COPD criteria.
Statistical methods
Crude prevalences were standardized for age and gender
using the population distribution from the Tromsø municipal-
ity of 1 January 2019. Frequency of characteristics was
determined according to HF and COPD status in the subjects
evaluated for both diseases. When describing the types of HF,
all subjects with HF were included, also those not evaluated
for COPD. Differences between groups were analysed with
χ2 statistics. Predictors of HF (irrespective of COPD co‐
morbidity) and COPD (irrespective of HF co‐morbidity) were
evaluated by logistic regression, adjusted for age, and rele-
vant explanatory variables associated with outcome with a
P‐value <0.1 were entered in the multivariable analysis.
Receiver operating characteristic (ROC) curves evaluating pre-
dictive value of variable from history, symptoms, signs, and
biomarkers were produced based on output (β) from
multivariable logistic regression with backward elimination,
with age more or less than 70 years as one of the explanatory
variables. SPSS statistical software version 26 (IBN, Armonk,
NY, USA) was used. Visual assessment of overlap between
HF, COPD, and mMRC ≥2 was made using a Venn diagram
(R package version 6.0.0.).
Ethical considerations
The Tromsø study protocol was performed in accordance
with the Declaration of Helsinki and was approved by the Re-
gional Committee for Medical and Health Research Ethics,
North Norway (2014/940/REK Nord). Written consent was
provided by all study participants.
Results
Inclusion of participants in the analyses is shown in Figure 1.
Out of 7316 attending the spirometry, valid measures were
obtained in 7247 with a mean age of 63.0 years (range 40–
84 years). Among these, 7110 answered the mMRC question-
naire and the question on cough, and a COPD diagnosis could
be made in 432 (6.1%). Age‐standardized prevalence of COPD
was 5.1% for men and 5.2% for women. Echocardiography
was performed in 2340 participants, 2106 of these also
attended spirometry. Evaluation of EF could be performed
in 2007 subjects (Figure 1), and among these, the mMRC
questionnaire was answered, and NT‐proBNP was analysed
in 1624 (mean age 64.0 years). A diagnosis of HF was
established in 155 (9.5%). The age‐standardized prevalence
of HF was 6.1% for men and 6.8% for women. Presence of
both HF and COPD could be evaluated in 1538 participants
(mean age 63.7 years), 51.5% were women, and 48.5% were
men. A diagnosis of COPD was established in 84 and HF in 139
participants, and 14 had both (Table 1, Figure 2). The preva-
lence of the diseases did not differ by sex but significantly
by age (P < 0.001); 64.8% of the 125 subjects with HF and
without COPD were aged 70 years or more compared with
28.8% of those with COPD (Table 1). Of those with COPD,
23% had mMRC = 0 with the diagnosis based solely on spi-
rometry and periods of daily cough. Among those with mMRC
≥2, 59% had HF, while 23.9% had COPD (Figure 2). Crackles
were heard in one out of five subjects with HF or COPD,
but basal bilateral crackles in only one out of 20. Wheezes
were heard more frequently in COPD than in HF (Table 1).
High frequency of FEV1 < LLN was found in both COPD and
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HF and reached 64.3% in subjects with both COPD and HF. In-
creased levels of NT‐proBNP were only found in the HF
groups. SpO2 values between 92% and 100% were found,
and an increased occurrence of SpO2 ≤95% was mainly found
among subjects with COPD (9%, P = 0.02).
Prediction of heart failure and chronic obstructive
pulmonary disease
Age‐adjusted odds ratios (ORs) in predicting HF and COPD are
shown in Table 2. Current smoking predicted COPD with an
OR of 15.8 but was not associated with HF. Reporting mMRC
≥2 was a particular strong predictor of HF, with an OR of 19.5
[95% confidence interval (CI) 11.3–33.7]. The corresponding
OR for COPD was 6.3 (95% CI 3.5–11.6). Reporting more
shortness of breath than usual on the examination day pre-
dicted both HF and COPD. Basal bilateral inspiratory crackles
were associated with both diseases but significantly only with
COPD (in the univariable analysis), whereas hearing wheezes
was a significant predictor of COPD only. Self‐reported hyper-
tension, atrial fibrillation, and myocardial infarction had ORs
for HF between 3.2 and 5.4 but did not predict COPD.
Self‐reported HF was a strong predictor of HF but was regis-
tered in only 17.1% of participants with an established HF.
HF could be established in only 21 of the 47 participants with
self‐reported HF. Among those with an established COPD,
31.6% reported to have the disease (Table 1), but overdiag-
nosis was as common as for HF. COPD predicted HF with an
OR of 1.97. NT‐proBNP was a strong predictor of HF and
not associated with COPD.
Multivariable analysis
In the multivariable analysis, basal bilateral inspiratory
crackles became significant predictors of HF, but not of COPD.
ROC curves based on the multivariable analyses and the rela-
tive weight of the included predictors in the scores applied
are shown in Figure 3. When assessing prediction of HF,
Figure 1 Flow chart of the participants of the seventh Tromsø study. COPD, chronic obstructive pulmonary disease; mMRC, modified Medical Research
Council; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide.
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self‐reported HF was excluded, and an area under the curve
(AUC) of 0.833 (95% CI 0.790–0.875) was obtained. Including
this variable gave similar ROC curve (AUC = 0.829). When in-
stead three levels of raised NT‐proBNP (<125 pg/mL,
≥125 pg/mL: <97.5 percentile and ≥97.5 percentile) were in-
cluded in the analysis, an AUC of 0.909 (95% CI 0.877–0.940)
was found. When assessing predictors of COPD, self‐reported
COPD was excluded, and an AUC of 0.829 (95% CI 0.783–
0.875) was found. When the variable self‐reported COPD
was included, a nominally higher AUC of 0.840 was found.
SpO2 ≤95% and C‐reactive protein ≥ 5 mg/L were not signifi-
cant predictors of COPD in the multivariable analysis.
Subtypes of heart failure
The frequency of establishing the three categories of HF was
38.7% for HFrEF, 21.3% for HFmrEF, and 40% for HFpEF. The
occurrence of HF type varied significantly with age (P = 0.003,
Table 3), HFrEF was the most frequent type in participants
younger than 70 years, while HFpEF was most frequent in
those older than 70 years (Figure 4). For COPD without con-
comitant HF, only a slight, and statistically insignificant, in-
crease in prevalence by age was observed (Table 1, Figure 4).
NT‐proBNP >125 pg/mL was found in 58.3% of the sub-
jects with HFrEF.
Sensitivity analysis
Only small and insignificant changes were found when predic-
tors of HF were evaluated by univariable and multivariable lo-
gistic regression in a somewhat extended sample of 1624
subjects. When predictors of COPD were evaluated in a sam-
ple of 7110 subjects, we found that statistical associations be-
came stronger for crackles and wheezes, but self‐reported
cardiovascular diseases and NT‐proBNP were still not associ-
ated with COPD. SpO2 ≤95% became more strongly associ-
ated with COPD with an OR of 3.5 (95% CI 2.3–5.4). ROC
curves based on multivariable analysis in the extended sam-
ples did not change the AUC.
Discussion
Main findings
Our study indicates that HF should always be considered in
patients reporting exertional dyspnoea when presenting in
primary care and also in the presence of COPD. We found
HF in as many as 59% of the participants who reported to
‘walk slower than people of the same age on the level be-
cause of breathlessness or has to stop for breath when walk-
ing at own pace on the level’ (mMRC = 2). The content of
mMRC = 2 corresponds rather closely to New York Heart As-
sociation grade 3,20 a scale mainly used for grading HF pa-
tients. We found a history of smoking to be the strongest
predictor of COPD, but smoking status is already recognized
as the most important information in early diagnosis of this
disease.19 We could confirm that crackles are a useful finding
in the diagnosis of HF but also frequently found in COPD.
Hearing crackles (any or basal) was not a significant indepen-
dent predictor of COPD in the multivariable analysis, which
may partly be explained by frequent occurrence of crackles
among current smokers.11 Wheezes were confirmed to be
Figure 2 Venn diagram showing associations between heart failure, chronic obstructive pulmonary disease (COPD), and modified Medical Research
Council (mMRC) ≥2 in 1538 participants.
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independent predictors of COPD.21 ROC analyses showed
that HF and COPD can be identified with similar ease based
on history, symptoms, and signs. HF was most strongly pre-
dicted when information on NT‐proBNP was included. How-
ever, NT‐proBNP ≥125 pg/mL had a low sensitivity for
HFrEF (58%).
Comparison with previous studies
To our knowledge, the 2016 ESC guidelines have not previ-
ously been applied in population‐based studies. The distribu-
tion of the HF subtypes was similar to what found in a recent
Danish study.22 In a Swedish register‐based study, including a
population aged 18 years or more, the prevalence of
age‐standardized HF was less than 2%.23 As only 40% had
the diagnosis based on echocardiography, this might have
caused a significant underdiagnosis, especially in patients
not requiring hospitalization where they are more likely to re-
ceive echocardiography. The Swedish figure is more compara-
ble with the rate of self‐reported HF in our study than the
actual prevalence of HF, which is more than twice as high.
We found a considerable underdiagnosis of HF, and one
may question whether the 2016 ESC diagnostic criteria are
sufficiently strict. Because the criteria for diastolic dysfunc-
tion have been sharpened, decreasing the prevalence in a
general population from 30% to 3%, this is unlikely.2 The
prevalence of COPD (with FEV1/FVC < LLN instead of <0.7
as diagnostic criterion, like in our study) was 7.3% in a Norwe-
gian study from 2006 to 2008.24 The lower prevalence in our
study (6.2%) may be partly explained by the inclusion of re-
spiratory symptoms as diagnostic criterion. Improved lung
health due to drop in smoking after 2008 may also have
played a role.
Table 2 Age‐adjusted odds ratios for heart failure (n = 139) and chronic obstructive pulmonary disease (n = 84) in univariable and mul-
tivariable analysis of clinical characteristics in 1538 participants
Odds ratio (OR) for heart failure Odds ratio (OR) for COPD
Univariable Multivariable Univariable Multivariable
OR 95% CI OR OR 95% CI OR
Male gender 1.1 0.8–1.5 0.9 0.6–1.4
Smoking
Never Ref Ref
Previous 1.2 0.8–1.7 5.7 2.6–12.7 3.2 1.3–7.5
Current 1.1 0.6–2.2 15.7 6.7–37.1 6.5 2.5–16.9
Respiratory symptoms
mMRC = 0–1 Ref
mMRC = 2 21.6 11.2–41.7 20.3 9.3–43.9 6.8 3.4–13.7 2.8 1.0–8.3
mMRC = 3–4 15.0 6.2–36.7 10.6 3.2–34.5 5.3 1. – 15.0 0.6 0.1–3.4
Daily cough in periods 1.5 1.0–2.4 1.4 0.8–2.4 4.4 2.8–6.7 3.4 1.9–6.3
More shortness of breath than normal
the examination day
2.2 1.4–3.7 1.4 0.7–2.8 3.7 2.2–6.2 2.2 1.2–4.3
Crackles
Any crackles 1.2 0.7–1.9 1.7 1.0–3.0 0.9 0.4–2.0
Basal bilateral inspiratory crackles 2.2 0.9–5.2 2.8 1.0–8.8 3.0 1.1–8.1 2.1 0.6–7.6
Wheezes
Any wheezes 1.0 0.6–1.5 2.0 1.3–3.3 1.3 0.6–2.9
Ordinary or long expiratory wheezes 0.8 0.4–1.6 2.2 1.2–4.0 1.5 0.5–4.1
Self‐reported diseases
Myocardial infarction ever 5.4 3.3–8.8 2.6 1.4–5.2 2.0 0.9–4.2 1.6 0.6–4.7
Angina pectoris ever 3.0 1.6–5.6 1.4 0.6–3.3 1.2 0.4–3.5
Atrial fibrillation ever 3.9 2.4–6.2 2.6 1.5–4.8 1.5 0.8–3.0
Heart failure 7.7 4.1–14.4 0.7 0.2–2.9
Hypertension ever 3.2 2.2 – 4.7 3.2 2.0–5.2 0.6 0.3–0.9 0.5 0.2–0.9
Diabetes ever 2.7 1.6–4.7 1.2 0.6–2.5 0.7 0.3–2.0
COPD ever 1.9 1.0–3.9 0.5 0.2–1.4 16.7 9.3–29.9
Asthma ever 1.7 1.0–2.8 1.0 0.5–2.0 6.3 3.9–10.1 3.5 1.9–6.4
COPD detected 2.0 1.1–3.7 1.5 0.6–4.1
Heart failure detected 1.9 1.0–3.6 1.6 0.6–4.7
FEV1 < LLN 2.5 1.5–4.2 1.6 0.7–3.4 19.0 11.6–31.0 13.6 7.4–25.0
NT‐proBNP >125 pg/mL 21.0 12.7–34.6 1.4 0.8–2.4
NT‐proBNP ≥97.5 percentile 11.2 6.9–18.1 0.9 0.4–2.4
C‐reactive protein ≥5 mg/L 1.5 0.8–2.7 1.8 0.9–3.6 1.3 0.5–3.2
SpO2 ≤95% 1.1 0.55–2.4 2.2 1.0–5.0 0.6 0.2–1.8
CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; LLN, lower limit of normal;
mMRC, modified Medical Research Council; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide.
Missing values are shown in Table 1. Clinical variables associated with the heart failure and COPD with a P < 0.1 are selected for the mul-
tivariable analysis, excluding self‐reported heart failure and self‐reported COPD, respectively. NT‐proBNP is also excluded from the multi-
variable analysis.
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A combination of HF and COPD seems to be less frequent
than previously reported. We found HF in 16.7% of those
with COPD, while the corresponding frequency in a
register‐based study from Taiwan was 28.9%.9 Among the
subjects with HF in our study, we found COPD co‐morbidity
in 10% only. In a Danish study, COPD was found in 35% of pa-
tients admitted with HF.25 This discrepancy may be partly
explained by selection of patients with severe disease in the
Danish study. The use of a fixed FEV1/FVC ratio of 0.7 as cri-
terion for COPD in the Danish study, instead of LLN, which we
used, has probably also contributed to a higher prevalence of
COPD.24 Several authors have warned against overdiagnosis
of COPD in HF, because pulmonary congestion can lead to
bronchial obstruction and a decreased FEV1/FVC ratio.
5,26,27
The strict criteria for COPD in our study (FEV1/FVC < LLN
and symptoms) have probably made overdiagnosis less likely.
The high frequency of coughing, smoking, FEV1 < LLN, and
self‐reported COPD in the group with both diseases
compared with those with HF only (Table 1) indicates that
overdiagnosis of COPD in subjects with HF has been a minor
problem.
Predictors of HF have often been evaluated in selected
populations, like in emergency departments. Shortness of
breath has been found to be of great importance in such
settings.6,28 Roalfe and co‐workers were not able to evaluate
shortness of breath as a diagnostic clue in their study,
because almost all patients referred from primary care for
cardiologic evaluation had this symptom, and the symptom
Figure 3 Receiver operating characteristic curves showing predictive value of smoking, self‐reported diseases, symptoms, and signs + N‐terminal
pro‐brain natriuretic peptide (NT‐proBNP) for heart failure, n = 1381, and chronic obstructive pulmonary disease (COPD), n = 1370. AUC, area under
the curve; CI, confidence interval; mMRC, modified Medical Research Council.
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was not graded.29 Crackles (crepitations) were found to be
sufficiently discriminating to be included in a clinical
prediction rule for HF, together with a history of myocardial
infarction, leg oedema, and a natriuretic peptide test. In a
larger study by Fonseca and co‐workers from 2004, 1058 pri-
mary care patients with history, symptoms, or signs indicating
HF were examined with echocardiography.17 Shortness of
breath was a strong predictor of HF, together with cardiovas-
cular disease, like in our study. Crackles (basal rales) were
more frequently registered and were more strongly associ-
ated with HF than in our study. One may question whether
selection bias has led to overrepresentation of patients with
crackles in this study. Crackles tend to be more frequent
when the HF gets more severe,30 and registration of crackles
in the study by Fonseca and co‐workers might have been in-
fluenced by the degree of suspicion of HF.
In a recent study of 1088 patients with HFrEF or HFmrEF,
19% had NT‐proBNP <125 pg/mL.31 This is probably
comparable with our results, with a frequency of 42% in the
HFrEF group and, by definition, 0% in the HFmrEF group.
Finding NT‐proBNP <125 pg/mL does not exclude HFrEF,
but with such low values, the prognosis is good.31
Strengths and limitations
Tromsø 7 had a 65% response rate. The Tromsø study has a
high external validity for the Norwegian population,12 but
people with poor health might have found it difficult to par-
ticipate and are probably underrepresented. The added inclu-
sion of subject who had been participating in previous waves
of the Tromsø study was probably only a minor source of er-
ror, because they had been randomly included in the previ-
ous surveys. They probably raised the mean age of the
study sample, but this was taken care of by applying
age‐standardized prevalence and age‐adjusted analysis. We
Table 3 Characteristics of 155 participants with heart failure in the seventh Tromsø study by type of heart failure
HFrEF HFmrEF HFpEF
n % n % n % P‐value
Men 37 61.7 16 48.5 22 35.5 0.02
Women 23 38.3 17 51.5 40 64.5
Age (years)
40–59 10 16.7 2 6.1 2 3.2 0.003
60–69 21 35.0 5 15.2 12 19.4
70–84 29 48.3 26 78.8 48 77.4
Smoking (2 missing)
Never 20 26.7 12 36.4 21 35.0 0.6
Previous 47 62.7 19 57.6 31 51.7
Current 8 10.7 2 6.1 8 13.3
Respiratory symptoms
mMRC
1 41 68.3 16 48.5 47 75.8 0.1
2 14 23.3 10 30.3 7 11.3
3–4 5 8.3 7 21.2 8 13.0
Daily cough in periods of the year (7 missing) 17 28.3 8 25.8 10 17.5 0.4
More shortness of breath than normal the examination day 10 16.7 6 18.2 11 17.7 1.0
Crackles and wheezes (11 missing)
Any crackle 12 21.1 6 20.0 13 22.8 0.9
Basal bilateral inspiratory crackles 3 5.3 2 6.7 4 7.0 0.9
Any wheezes 16 28.1 3 10.0 14 24.6 0.2
Ordinary or long expiratory wheezes 6 10.5 2 6.7 6 10.5 0.8
Self‐reported diseases
Myocardial infarction (11 missing) 13 22.8 9 30.0 14 24.6 0.8
Angina pectoris (15 missing) 7 13.0 5 17.9 7 12.1 0.8
Atrial fibrillation (15 missing) 15 27.8 11 39.3 12 20.7 0.2
Heart failure (18 missing) 11 20.0 7 25.9 4 7.3 0.057
Hypertension (9 missing) 32 57.1 24 77.4 39 66.1 0.2
Diabetes (8 missing) 13 22.8 6 20.7 3 4.9 0.015
COPD (12 missing) 5 8.9 3 10.3 9 15.5 0.5
Asthma (12 missing) 9 16.1 6 20.7 13 22.4 0.7
FEV1 < LLN (10 missing) 14 23.7 4 12.9 8 14.5 0.3
COPD, defined by spirometry and symptoms (16 missing) 6 10.3 2 6.9 6 11.5 0.8
NT‐proBNP >125 pg/mL 35 58.3 33 100 62 100 <0.001
NT‐proBNP ≥97.5 percentile 18 30.0 17 51.5 16 25.8 0.03
C‐reactive protein ≥5 mg/L (1 missing) 8 13.6 5 15.2 4 6.5 0.3
SpO2 ≤95% 4 6.7 1 3.0 7 11.3 0.3
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; HFmrEF, heart failure with mid‐range ejection frac-
tion; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LLN, lower limit of normal;
mMRC, modified Medical Research Council; NT‐proBNP, N‐terminal pro‐brain natriuretic peptide.
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applied the new diagnostic criteria for HF, and reading of
echocardiography was blinded for other information about
the participants. Regarding the diagnosis of COPD, we in-
cluded respiratory symptoms among the diagnostic criteria,
which is now recommended in GOLD guidelines.19 However,
post‐bronchodilator spirometry was not carried out, which
might have led to overdiagnosis in some participants.32 Re-
corded lung sounds have not been applied in previous studies
on prediction of HF and COPD. The classification of the
sounds was also blinded, and an objective identification of
lung sounds was thus made possible. We were not able to
evaluate other clinical signs, such as oedema and neck–vein
distension. Relying on self‐report for previous diseases intro-
duces the limitation of recall bias. Further, self‐reported dis-
eases do not accurately reflect the diseases diagnosed in
health care. In a study from the USA, only 38% of participants
with a diagnosis of HF found in medical records reported to
have the disease.33 Although such discordance might be less
pronounced in other diseases, the significance of
self‐reported diseases should always be questioned.
Conclusions
The study indicates that a doctor with considerable certainty
may identify HF and COPD and also differentiate the diseases
from each other, based on history, symptoms, and signs. In
general practice, when an elderly patient present with short-
ness of breath, both diseases should be considered. Abnormal
lung sounds may be found in both diseases, previous
cardiovascular disease points at HF, while a history of smoking
points at COPD. Wheezes were independent predictors of
COPD, while NT‐proBNP was not associated with COPD. The
threshold should be low for ordering echocardiography or spi-
rometry to verify the suspected cause of dyspnoea.
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pants] and three types of HF (based on 1624 participants) by age in the
seventh Tromsø study. HFmrEF, HF with mid‐range ejection fraction;
HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejec-
tion fraction.
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